Jefferies London 2026: Zealand Pharma CEO Adam Steensberg gives an update on the company's amylin program and comments on recent data from its Boehringer partnered glucagon/GLP-1
From BiotechTV - News · 00:14:11
Show by BiotechTV
He shares his strong belief that for most people taking obesity medicines going forward, tolerability could be the most important factor of choice, which is amylin's strong suit.
More episodes of BiotechTV - News
More episodes
- Jefferies London 2026: Forbion, the most active lead investor in private biotech financing rounds globally last year, raised €2.3 billion across two new funds last month
- Jefferies London 2026: IDEAYA Biosciences Founder & CEO Yujiro Hata shares an update on darovasertib, which is in front of FDA for Uveal Melanoma, and talks DLL3 and PRMT5
- Jefferies London: When Celgene's powerhouse myeloma treatments emerged, it wasn't known that they were protein degraders. With today's advances in science, C4 aims to have a best in class degrader
- Jefferies London 2026: APOL1-mediated kidney disease affects over 1 million people in the United States - Maze Therapeutics hopes to deliver a solution
- Jefferies London 2026: Marea Therapeutics' CEO Josh Lehrer describes the ANGPTL4 target for targeting triglycerides (Marea is first in class) and compares and contrasts it to ANGPTL3 and APOE3
- Jefferies London 2026: The phase 3 OPERA-01study of Olema's CERAN + SERD, palazestrant, is setting up to be one of biotech's key readouts and is quickly approaching and scheduled to read in 1Q27
- Jefferies London 2026: Erasca is racing to be the next big story in the RAS space (in both pancreatic and lung) and believes it may have a best in class asset with high potency
- Jefferies London 2026: With two FDA filings under review and other programs in late stage, Praxis is in a pivotal moment - CEO Marcio Souza updates us on all the moving pieces
- Jefferies London 2026: A top biotech CEO (Roivant's Matt Gline) and top investor (Affinity Asset Advisors' Patrick Nosker) talk running biotech companies and investing in them
- Jefferies London 2026: Generate Biomedicines' CEO Mike Nally describes the rationale behind a recent CAR-T deal with Anthropic, updates us on the company's TSLP, and more
PodSearch is a free, independent podcast search engine. Read about PodSearch, the privacy policy or contact us.